BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 1-Year Low at $4.81

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report)'s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $4.81 and last traded at $4.82, with a volume of 715402 shares trading hands. The stock had previously closed at $5.05.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a "buy" rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Monday, January 8th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $13.29.

BioCryst Pharmaceuticals Trading Down 7.1 %

The business has a 50 day simple moving average of $5.40 and a two-hundred day simple moving average of $5.82. The stock has a market cap of $966.84 million, a price-to-earnings ratio of -3.97 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to the consensus estimate of $89.19 million. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. boosted its position in BioCryst Pharmaceuticals by 7,385.4% during the 2nd quarter. Point72 Asset Management L.P. now owns 4,004,700 shares of the biotechnology company's stock valued at $28,193,000 after purchasing an additional 3,951,200 shares during the period. Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 40.3% during the 1st quarter. Vanguard Group Inc. now owns 13,207,040 shares of the biotechnology company's stock valued at $214,746,000 after purchasing an additional 3,794,135 shares during the period. State Street Corp boosted its position in BioCryst Pharmaceuticals by 47.5% during the 2nd quarter. State Street Corp now owns 11,004,803 shares of the biotechnology company's stock valued at $116,431,000 after purchasing an additional 3,542,051 shares during the period. Braidwell LP boosted its position in BioCryst Pharmaceuticals by 92.1% during the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company's stock valued at $37,970,000 after purchasing an additional 2,571,100 shares during the period. Finally, Norges Bank acquired a new position in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $13,278,000. Institutional investors and hedge funds own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.